Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05014399 · ClinicalTrials.gov registry record

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

A clinical trial of Cognitive Impairment and Cognitive Decline, sponsored by Joseph McCollom.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT05014399 is a study of Cognitive Impairment and Cognitive Decline that is actively recruiting participants, run by Joseph McCollom. The registered enrollment target is 60 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05014399, a study of Cognitive Impairment and Cognitive Decline, is actively recruiting participants, sponsored by Joseph McCollom.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.

Study Locations (1)

Indiana

  • Parkview Cancer Institute - Fort Wayne

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-09-20
Est. Completion 2031-10

Sponsor

Joseph McCollom

1 total trials

What the Registry Record Tells You About NCT05014399

The ClinicalTrials.gov registry entry for NCT05014399 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (91% lower). The listed sponsor is Joseph McCollom, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.

NCT05014399 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT05014399 about?

NCT05014399 is a clinical study titled "Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy". The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficultie...

What is the current status of trial NCT05014399?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2021-09-20. Estimated completion is 2031-10.

What conditions does trial NCT05014399 study?

This clinical trial studies the following conditions: Cognitive Impairment, Cognitive Decline, Cognitive Dysfunction, Cognitive Change, Chemotherapy Effect.

Who is sponsoring clinical trial NCT05014399?

This trial is sponsored by Joseph McCollom, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05014399 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.